Photophobia
17
3
3
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.9%
1 terminated out of 17 trials
87.5%
+1.0% vs benchmark
12%
2 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (17)
Comparison Between Spectacles and Contact Lenses
Light Exposure, Migraine Outcomes, and Sleep Quality
Use of Tinted Contact Lenses for Concussion-Related Light Sensitivity
Pilot Study of Neurofeedback for Photosensitivity in Mild Traumatic Brain Injury
Objectively Diagnose and Monitor Treatment of Light Sensitivity
Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
Improving Glare and Visual Comfort for Patients With Visual Impairment
Performance and Tolerability of the Medical Device LACRIACT
Migraine Headache Mitigation Utilizing Avulux
Mindfulness Based Cognitive Therapy Modified for Visual Symptoms (MBCT-vision)
Biomarker for Cystinosis Disease: BioCystinosis (BioCystinosis)
Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Child and Adolescent Patients With Migraine
How Can we Treat Photophobia in Migraine
Functional MRI Study of Cortical Modifications to Light Stimulation in Patients With Photophobia
The Head Injury-associated Photosensitivity and Pupillary Function (HIPP) Study
Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Patients With Migraine
An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine Attack